Hearing and Other Neurologic Problems

Area of Science:

• Pediatric Oncology
• Neuro-oncology
• Ototoxicology

Background:

• Childhood cancer therapies, including chemotherapy (platinum, vinca alkaloids), cranial radiation, and certain medications (aminoglycosides, loop diuretics), can lead to significant ototoxicity and neurologic toxicities.
• These treatment-related toxicities pose long-term challenges for cancer survivors, impacting their quality of life and functional status.

Purpose of the Study:

• To provide a comprehensive overview of ototoxicity and other neurologic toxicities associated with childhood cancer treatment.
• To discuss the challenges these toxicities present for survivors.
• To outline current recommendations for surveillance and clinical management of these adverse effects in pediatric cancer survivors.

Main Methods:

• Literature review of studies on ototoxicity and neurologic toxicities in pediatric cancer.
• Analysis of treatment modalities and supportive care agents implicated in these toxicities.
• Synthesis of current guidelines for surveillance and management strategies.

Main Results:

• Common therapeutic agents and interventions in pediatric cancer treatment are associated with a high risk of ototoxicity and neurologic damage.
• These toxicities can manifest as hearing impairment, balance problems, and other neurological deficits, persisting long after treatment completion.
• Effective surveillance and timely clinical management are crucial for mitigating the impact of these adverse events.

Conclusions:

• Ototoxicity and neurologic toxicities are critical, often life-altering, adverse effects of childhood cancer treatment.
• Long-term surveillance and proactive clinical management are essential for improving outcomes and quality of life for childhood cancer survivors.
• Further research is needed to develop more targeted and less toxic treatment strategies.